2007;98:1297C1302
2007;98:1297C1302. agonist anti-CD137 monoclonal antibodies (mAbs), which was substantiated against poorly GNG12 immunogenic B16 melanomas (B16-OVA and B16.F10) and TC-1 lung carcinomas. Effector CD8+ T cells were sufficient to mediate complete tumor eradications. Accordingly, there was an intensely synergistic enhancement of cytotoxic T lymphocytes (CTL)-mediated immunity against the tumor antigens OVA and tyrosine-related protein-2 (TRP-2).…